Gene therapy targets inner retina to combat blindness

mediabest

Gene therapy to the inner retina prevented blindness in a mouse model of the neuro-degenerative disorder CLN3 Batten disease. Adeno-associated viral (AAV)-mediated expression of the human CLN3 gene led to significant survival of bipolar cells and pre-served retinal function, as reported in the peer-reviewed journal Human Gene Therapy.

Batten disease is a group of fatal, inherited lysosomal storage disorders that predominantly affect children. The most prevalent form is CLN3 disease, for which there is no cure. Retinal degeneration and resulting vision loss is one of the symptoms.

Robin Ali, UCL Institute of Ophthalmology, London, and coauthors state that “Bipolar cell specific expression of human CLN3 rescues the retinal phenotype of Cln3-deficient mice.” They show that the Cln3-deficient mice suffer a decline in inner retinal function resulting from the death of rod bipolar cells.

Source: Read Full Article

Related posts:
  1. Orthostatic hypotension during therapy not tied to CVD events
  2. Created for anthrax attacks, cold plasma air filter is being prepped to combat COVID-19
  3. Persian cat Mr Magoo needed surgery to prevent blindness caused by his flat face
  4. New research suggests failure to retrieve relevant details from memory may underlie face blindness
  5. Cyberbullying ‘shield’ app uses AI to combat social media trolls